Alzheimer's & dementia (Amsterdam, Netherlands)
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Validation of regression-based change formulae for mild cognitive impairment and Alzheimer's disease..
16:-.
2024
-
Functional measures and AD biomarkers among Hispanic and White non-Hispanic older adults..
16:-.
2024
-
Amyloid beta-independent sleep markers associated with early regional tau burden and cortical thinning..
16:-.
2024
-
Racial/ethnic differences in neuropsychiatric disturbances associated with incident dementia..
16:-.
2024
-
Cognitive and functional performance and plasma biomarkers of early Alzheimer's disease in Down syndrome..
16:-.
2024
-
An explainable machine learning model of cognitive decline derived from speech..
15:-.
2023
-
Leveraging longitudinal diffusion MRI data to quantify differences in white matter microstructural decline in normal and abnormal aging..
15:-.
2023
-
Memory and language cognitive data harmonization across the United States and Mexico..
15:-.
2023
-
Face Name Associative Memory Exam and biomarker status in the ARMADA study: Advancing reliable measurement in Alzheimer's disease and cognitive aging..
15:-.
2023
-
Harmonization of cognitive screening tools for dementia across diverse samples: A simulation study..
15:-.
2023
-
Relation of modifiable lifestyle and mood factors to cognitive concerns among participants and their study partners in the A4 screen data..
15:-.
2023
-
Clinical utility of an antibody-free LC-MS method to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 Study..
15:-.
2023
-
Differential involvement of hippocampal subfields in the relationship between Alzheimer's pathology and memory interference in older adults..
15:-.
2023
-
Computerized cognitive practice effects in relation to amyloid and tau in preclinical Alzheimer's disease: Results from a multi-site cohort..
15:-.
2023
-
Association of cardiovascular risk factors and blood biomarkers with cognition: The HABS-HD study..
15:-.
2023
-
Grip strength, gait speed, and trajectories of cognitive function in community-dwelling older adults: A prospective study..
15:-.
2023
-
A data-driven examination of apathy and depressive symptoms in dementia with independent replication..
15:-.
2023
-
Higher literacy is associated with better white matter integrity and cognition in middle age..
14:-.
2022
-
Factors influencing the participation of Black and White Americans in Alzheimer's disease biomarker research..
14:-.
2022
-
Age differences in the association between sleep and Alzheimer's disease biomarkers in the EPAD cohort..
14:-.
2022
-
Preferences of NIA Alzheimer's Disease Research Center participants regarding remote assessment during the COVID-19 pandemic..
14:-.
2022
-
Cognitive dysfunction and the 25-item National Eye Institute Visual Function Questionnaire..
14:-.
2022
-
Emotional characteristics of socially isolated older adults with MCI using tablet administered NIH toolbox: I-CONECT study..
14:-.
2022
-
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease..
14:-.
2022
-
Associations of the Lifestyle for Brain Health index with longitudinal cognition and brain amyloid beta in clinically unimpaired older adults: Findings from the Wisconsin Registry for Alzheimer's Prevention..
14:-.
2022
-
Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society..
14:-.
2022
-
Development and implementation of an electronic Clinical Dementia Rating and Financial Capacity Instrument-Short Form..
14:-.
2022
-
Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology..
14:-.
2022
-
Physical activity is associated with increased resting-state functional connectivity in networks predictive of cognitive decline in clinically unimpaired older adults..
14:-.
2022
-
IFITM3.
14:-.
2022
-
Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI..
14:-.
2022
-
Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort..
14:-.
2022
-
Online monitoring of financial capacity in older adults: Feasibility and initial findings..
14:-.
2022
-
Examining the role of repeated test exposure over 12 months across ADNI protocols..
14:-.
2022
-
A study of the longitudinal changes in multiple cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers on converter and non-converter Alzheimer's disease subjects with consideration for their amyloid beta status..
14:-.
2022
-
Blood metabolites predicting mild cognitive impairment in the study of Latinos-investigation of neurocognitive aging (HCHS/SOL)..
14:-.
2022
-
Vascular risk profile and white matter hyperintensity volume among Mexican Americans and non-Hispanic Whites: The HABLE study..
14:-.
2022
-
APOE.
14:-.
2022
-
Neurodegeneration from the AT(N) framework is different among Mexican Americans compared to non-Hispanic Whites: A Health & Aging Brain among Latino Elders (HABLE) Study..
14:-.
2022
-
Caregiver appraisals of lucid episodes in people with late-stage Alzheimer's disease or related dementias..
14:-.
2022
-
Medicare's Annual Wellness Visit and diagnoses of dementias and cognitive impairment..
14:-.
2022
-
Neuroimaging correlates of Stages of Objective Memory Impairment (SOMI) system..
13:-.
2021
-
Subtle mistakes in self-report surveys predict future transition to dementia..
13:-.
2021
-
Normative data for the Brief Spanish-English Verbal Learning Test for representative and diverse Hispanics/Latinos: Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)..
13:-.
2021
-
MRI biomarkers of small vessel disease and cognition: A cross-sectional study of a cognitively normal Mexican American cohort..
13:-.
2021
-
Relationship between objectively measured physical activity on neuropathology and cognitive outcomes in older adults: Resistance versus resilience?.
13:-.
2021
-
Unsupervised mobile cognitive testing for use in preclinical Alzheimer's disease..
13:-.
2021
-
Cortical thickness across the lifespan in a Colombian cohort with autosomal-dominant Alzheimer's disease: A cross-sectional study..
13:-.
2021
-
Head injury is associated with tau deposition on PET in MCI and AD patients..
13:-.
2021
-
Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial..
13:-.
2021
-
Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease..
13:-.
2021
-
Fractal motor activity regulation and sex differences in preclinical Alzheimer's disease pathology..
13:-.
2021
-
The Health & Aging Brain among Latino Elders (HABLE) study methods and participant characteristics..
13:-.
2021
-
Measurement batch differences and between-batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values..
13:-.
2021
-
The relationship of semantic intrusions to different etiological subtypes of MCI and cognitively healthy older adults..
13:-.
2021
-
Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer's disease..
13:-.
2021
-
Trajectories of cognitive function in community-dwelling older adults: A longitudinal study of population heterogeneity..
13:-.
2021
-
Conversion between the Modified Mini-Mental State Examination (3MSE) and the Mini-Mental State Examination (MMSE)..
13:-.
2021
-
Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know..
13:-.
2021
-
Pilot study of an Alzheimer's disease risk assessment program in a primary care setting..
13:-.
2021
-
Uniform data set language measures for bvFTD and PPA diagnosis and monitoring..
13:-.
2021
-
Diminished Learning Over Repeated Exposures (LORE) in preclinical Alzheimer's disease..
12:-.
2021
-
Development and internal validation of a predictive model of cognitive decline 36 months following elective surgery..
13:-.
2021
-
Theoretical frameworks and approaches used within the Reserve, Resilience and Protective Factors professional interest area of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment..
12:-.
2020
-
A recommended "minimum data set" framework for SD-OCT retinal image acquisition and analysis from the Atlas of Retinal Imaging in Alzheimer's Study (ARIAS)..
12:-.
2020
-
Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study..
12:-.
2020
-
Multi-time-point data preparation robustly reveals MCI and dementia risk factors..
12:-.
2020
-
Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab..
12:-.
2020
-
Depression screening in cognitively normal older adults: Measurement bias according to subjective memory decline, brain amyloid burden, cognitive function, and sex..
12:-.
2020
-
Depressive symptoms and CSF Alzheimer's disease biomarkers in relation to clinical symptom onset of mild cognitive impairment..
12:-.
2020
-
Dual sensory impairment in older adults and risk of dementia from the GEM Study..
12:-.
2020
-
Diagnosed prevalence of Alzheimer's disease and related dementias in Medicare Advantage plans..
12:-.
2020
-
Relationships between big-five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease..
12:-.
2020
-
BHA-CS: A novel cognitive composite for Alzheimer's disease and related disorders..
12:-.
2020
-
in vivo.
12:-.
2020
-
Amyloid duration is associated with preclinical cognitive decline and tau PET..
12:-.
2020
-
APOE.
12:-.
2020
-
Deciphering the factors that influence participation in studies requiring serial lumbar punctures..
12:-.
2020
-
Nonlinear Z-score modeling for improved detection of cognitive abnormality..
797-808.
2019
-
Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition..
700-709.
2019
-
Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study..
670-678.
2019
-
Plasma lipocalin-2 levels in the preclinical stage of Alzheimer's disease..
646-653.
2019
-
Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition..
510-519.
2019
-
Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer's Coordinating Centers volunteers..
333-339.
2019
-
Measuring longitudinal cognition: Individual tests versus composites..
74-84.
2019
-
The Role of Inflammation after Surgery for Elders (RISE) study: Study design, procedures, and cohort profile..
752-762.
2019
-
Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease..
595-598.
2018
-
The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions..
130-142.
2017
-
The relationship between recall of recently versus remotely encoded famous faces and amyloidosis in clinically normal older adults..
121-129.
2017
-
Long-term impact of intensive lifestyle intervention on cognitive function assessed with the National Institutes of Health Toolbox: The Look AHEAD study..
41-48.
2017
-
A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: The preclinical AD consortium..
147-155.
2017
-
Variability in medication taking is associated with cognitive performance in nondemented older adults..
210-213.
2017
-
δ scores predict mild cognitive impairment and Alzheimer's disease conversions from nondemented states..
214-221.
2017
-
Macrovascular and microvascular cerebral blood flow in adults at risk for Alzheimer's disease..
48-55.
2017
-
The effect of the top 20 Alzheimer disease risk genes on gray-matter density and FDG PET brain metabolism..
53-66.
2016
-
Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care..
15-22.
2016
-
A comparison of theoretical and statistically derived indices for predicting cognitive decline..
171-181.
2016
-
An individual with human immunodeficiency virus, dementia, and central nervous system amyloid deposition..
1-5.
2016
-
Meeting physical activity recommendations may be protective against temporal lobe atrophy in older adults at risk for Alzheimer's disease..
14-7.
2016
-
Thrombopoietin is associated with δ's intercept, and only in Non-Hispanic Whites..
35-42.
2016
-
Novel verbal fluency scores and structural brain imaging for prediction of cognitive outcome in mild cognitive impairment..
113-22.
2016
-
Cerebrospinal fluid ratios with Aβ42 predict preclinical brain β-amyloid accumulation..
27-38.
2016
-
Development of a subjective cognitive decline questionnaire using item response theory: a pilot study..
1:429-439.
2015
-
Intracranial Arterial 4D-Flow is Associated with Metrics of Brain Health and Alzheimer's Disease..
1:420-428.
2015
-
Predicting conversion to dementia in a memory clinic: A standard clinical approach compared with an empirically defined clustering method (latent profile analysis) for mild cognitive impairment subtyping..
1:447-54.
2015
-
Amyloid burden, cortical thickness, and cognitive function in the Wisconsin Registry for Alzheimer's Prevention..
1:160-169.
2015
-
Plasma BDNF levels associate with Pittsburgh compound B binding in the brain..
1:187-193.
2015
-
THE QUICK DEMENTIA RATING SYSTEM (QDRS): A RAPID DEMENTIA STAGING TOOL..
1:249-259.
2015
-
Traits of patients who screen positive for dementia and refuse diagnostic assessment..
1:236-241.
2015
-
Hippocampal subfield surface deformity in non-semantic primary progressive aphasia..
1:14-23.
2015
-
Subjective memory complaints, cortical thinning, and cognitive dysfunction in middle-aged adults at risk for AD..
1:33-40.
2015
-
Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study..
1:339-348.
2015
-
Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI
2022
-
Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI
2022
-
Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI
2022
Identity
International Standard Serial Number (ISSN)